We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Halts Andrx's ANDAs In Wake of cGMP Observations
FDA Halts Andrx's ANDAs In Wake of cGMP Observations
September 8, 2005
The FDA’s Florida District office has placed Andrx’s pending abbreviated new drug applications (ANDAs) on hold due to manufacturing problems — a move that could potentially threaten the generic firm’s portfolio of previously approved drugs.